非酒精性脂肪性肝病：回顾历史,展望未来

doi:10.3969/j.issn.1672-5069.2016.02.001

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (2): 129-131.doi: 10.3969/j.issn.1672-5069.2016.02.001

• 述评 • 下一篇

非酒精性脂肪性肝病：回顾历史,展望未来

曾民德

200127 上海市交通大学医学院附属仁济医院消化科

收稿日期:2016-01-01 出版日期:2016-03-10 发布日期:2016-03-04
作者简介:曾民德,男,80岁,主任医师,教授。主要从事脂肪肝纤维化及消化临床药理的基础和临床研究

Achievements and perspectives in nonalcoholic fatty liver diseases

Zeng Mingde

Department of Gastroenterology, Renji Hospital, Affiliated to Jiaotong University School of Medicine, Shanghai

Received:2016-01-01 Online:2016-03-10 Published:2016-03-04

摘要/Abstract

摘要： 脂肪肝（Fatty liver,FL）一词是1844年Rokitansky在肥胖患者病理检查发现肝脏有脂肪贮积而命名的。1980年Ludwig et al将无饮酒史的肥胖和糖尿病（DM）患者出现的FL和肝小叶炎症病变命名为非酒精性脂肪性肝炎（NASH）后,才步入NAFLD研究时代。35年来,其研究发展的主要亮点如下。

关键词: 非酒精性脂肪性肝病, 回顾, 展望

Key words: Nonalcoholic fatty liver diseases, Achievements, Perspective

曾民德. 非酒精性脂肪性肝病：回顾历史,展望未来[J]. 实用肝脏病杂志, 2016, 19(2): 129-131.

Zeng Mingde. Achievements and perspectives in nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 129-131.

[1] Sanyal AJ. NASH:A global health problem. Hepatol Res,2011, 41（7）:670-674.
[2] Tiniakos DG,Vos MB,Brunt EM. Nonalcoholic fatty liver disease:pathology and pathogenesis. Annu Rev Pathol,2010,5：145-171.
[3] Than NN,Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis,2015,239（1）:192-202.
[4] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52（5）:1836-1846.
[5] Cusi K. Role of obesity and lipotoxicity in the development of
nonalcoholic steatohepatitis:pathophysiology and clinicalimplications. Gastroenterology,2012,142（4）:711-725,e6.
[6] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis:the central role of nontriglyceride fatty acid metabolites. Hepatology,2010,52（2）:774-788.
[7] Esser N,Legrand-Poels S,Piette J,et al. Inflammation as a link between obesity,metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract,2014,105（2）:141-150.
[8] LaBrecque DR,Abbas Z,Anania F,et al. World Gastroenterology Organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48（6）:467-473.
[9] EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015,63（1）:237-264.
[10] Musso G,Gambino R,Cassader M,et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology,2010,52（1）:79-104.
[11] 曾民德. PIVENS及其相关的后续研究与非酒精性脂肪性肝病治疗的未来方向. 肝脏,2014,19（1）:53-56.
[12] Sanyal AJ,Friedman SL,McCullough AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology,2015,61（4）:1392-1405.
[13] Anstee QM,McPherson S,Day CP. How big a problem is non-alcoholic fatty liver disease BMJ,2011,343（d38）:97.
[14] Nascimbeni F,Pais R,Bellentani S,et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013, 59（4）:859-871.
[15] Ratziu V,Goodman Z,Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol,2015,62（Suppl 1）:S65-75.
[16] Matherly SC,Puri P. Mechanisms of simple hepatic steatosis: not so simple after all. Clin Liver Dis,2012,16（3）:505-524.
[17] Byrne CD,Targher G. NAFLD:a multisystem disease. J Hepatol,2015,62（Suppl 1）:S47-64.
[18] Marchesini G,Mazzotti A. NAFLD incidence and remission:only a matter of weight gain and weight loss J Hepatol,2015,62（1）: 15-17.
[19] Caldwell SH,Ikura Y,Iezzoni JC,et al. Has natural selection in human populations produced two types of metabolic syndrome （with and without fatty liver） J Gastroenterol Hepatol,2007,22 （Suppl）:S11-19.
[20] Armstrong MJ,Adams LA,Canbay A,et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014,59（3）:1174-1197.
[21] Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006,444（7121）:860-867.
[22] Gallagher EJ,LeRoith D. Epidemiology and molecular mechanisms tying obesity,diabetes,and the metabolic syndrome with cancer. Diabetes Care,2013,36 （Suppl 2）:S233-239.
[23] Arnold M,Pandeya N,Byrnes G,et al. Global burden of cancer attributable to high body-mass index in 2012:a population-based study. Lancet Oncol,2015,16（1）:36-46.
[24] Stickel F,Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma:mechanisms and implications. Gut,2010,59（10）:1303-1307.
[25] Tsedensodnom O,Sadler KC. ROS:redux and paradox in fatty liver disease. Hepatology,2013,58（4）:1210-1212

非酒精性脂肪性肝病：回顾历史,展望未来

Achievements and perspectives in nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[10]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[11]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[12]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[13]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[14]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[15]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.